Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Psoriatic Arthritis Drugs at a Glance, 2023

Mary Choy, PharmD, BCGP, FASHP  |  

References

  1. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013 Nov;69(5):729–735.
  2. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019 Jan;71(1):5–32.
  3. The National Psoriasis Foundation. About psoriatic arthritis. 2022 Jun 2. https://www.psoriasis.org/about-psoriatic-arthritis/.
  4. FDA approves Cyltezo, the first interchangeable biosimilar to Humira [news release]. U.S. Food & Drug Administration. 2021 Oct 18. https://www.fda.gov/news-events/press-announcements/fda-approves-cyltezo-first-interchangeable-biosimilar-humira.
  5. Otezla prescribing information. U.S. Food & Drug Administration. 2021 Dec. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/205437s011lbl.pdf.
  6. Enbrel prescribing information. U.S. Food & Drug Administration. 2022 Jun. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/103795s5591lbl.pdf.
  7. Erelzi prescribing information. U.S. Food & Drug Administration. 2022 Nov. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761042s018lbl.pdf.
  8. Eticovo prescribing information. U.S. Food & Drug Administration. 2019 Apr. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761066s000lbl.pdf.
  9. Remicade prescribing information. U.S. Food & Drug Administration. 2021 Oct. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103772s5401lbl.pdf.
  10. Inflectra prescribing information. U.S. Food & Drug Administration. 2021 Jun. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125544s018lbl.pdf.
  11. Renflexis prescribing information. U.S. Food & Drug Administration. 2022 Jan. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761054Orig1s029lbl.pdf.
  12. Ixifi prescribing information. U.S. Food & Drug Administration. 2020 Jan. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761072s006lbl.pdf.
  13. Avsola prescribing information. U.S. Food & Drug Administration. 2021 Sep. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761086s001lbl.pdf.
  14. Humira prescribing information. U.S. Food & Drug Administration. 2021 Feb. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125057s417lbl.pdf.
  15. Amjevita prescribing information. U.S. Food & Drug Administration. 2022 Jul. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761024s010lbl.pdf.
  16. Cyltezo prescribing information. U.S. Food & Drug Administration. 2022 Mar. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761058Orig1s011lbl.pdf.
  17. Hyrimoz prescribing information. U.S. Food & Drug Administration. 2022 Jul. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761071s010s012lbl.pdf.
  18. Hulio prescribing information. U.S. Food & Drug Administration. 2022 Jul. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761154s002lbl.pdf.
  19. Yusimry prescribing information. U.S. Food & Drug Administration. 2021 Dec. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761216s000lbl.pdf.
  20. Abrilada prescribing information. U.S. Food & Drug Administration. 2022 Jul. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761118s006lbl.pdf.
  21. Idacio prescribing information. U.S. Food & Drug Administration. 2022 Dec. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761255s000lbl.pdf.
  22. Hadlima prescribing information. U.S. Food & Drug Administration. 2022 Dec. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761059Orig1s007lbl.pdf.
  23. Cimzia prescribing information. U.S. Food & Drug Administration. 2022 Dec. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125160s305lbl.pdf.
  24. Simponi prescribing information. U.S. Food & Drug Administration. 2019 Sep. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125289s146lbl.pdf.
  25. Simponi Aria prescribing information. U.S. Food & Drug Administration. 2021 Feb. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125433s032lbl.pdf.
  26. Orencia prescribing information. U.S. Food & Drug Administration. 2021 Dec. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125118s240lbl.pdf.
  27. Stelara prescribing information. U.S. Food & Drug Administration. 2022 Jul. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125261s161lbl.pdf.
  28. Siliq prescribing information. U.S. Food & Drug Administration. 2017 Feb. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf.
  29. Taltz prescribing information. U.S. Food & Drug Administration. 2022 Jul. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125521s024lbl.pdf.
  30. Cosentyx prescribing information. U.S. Food & Drug Administration. 2021 Dec. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125504_S050_S051lbl.pdf.
  31. Tremfya prescribing information. U.S. Food & Drug Administration. 2020 Jul. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761061s007lbl.pdf.
  32. Skyrizi prescribing information. U.S. Food & Drug Administration. 2022 Sep. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761105s009s010lbl.pdf.
  33. Ilumya prescribing information. U.S. Food & Drug Administration. 2022 Dec. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761067s014lbl.pdf.
  34. Xeljanz prescribing information. U.S. Food & Drug Administration. 2021 Dec. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203214s028,208246s013,213082s003lbl.pdf.
  35. Rinvoq prescribing information. U.S. Food & Drug Administration. 2022 Oct. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211675s010lbl.pdf.

*Designated by the FDA as interchangeable with adalimumab (Humira), meaning adalimumab-adbm (Cyltezo) can be substituted for its reference product at the pharmacy, without additional approvals from the prescribing doctor, state law permitting. This is the first biosimilar for the treatment of a rheumatic condition to receive approval for interchangeability.

Related Articles

    Psoriatic Arthritis Treatment Update

    About 30% of patients with psoriasis have psoriatic arthritis (PsA), a complex, multi-faceted, chronic, inflammatory musculoskeletal and skin disease for which the treatment has changed considerably over the past few years.1 Biosimilars and other new drugs have become a therapeutic turning point for many patients suffering from rheumatic illnesses, including PsA. The treatment of PsA…

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    kenary820 / shutterstock.com

    Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis

    Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

    MicroOne / shutterstock.com

    Rheumatology Drugs at a Glance, Part 2: Psoriasis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…